305 related articles for article (PubMed ID: 32013157)
1. HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?
Losson H; Schnekenburger M; Dicato M; Diederich M
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32013157
[TBL] [Abstract][Full Text] [Related]
2. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
[TBL] [Abstract][Full Text] [Related]
3. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
7. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
[TBL] [Abstract][Full Text] [Related]
8. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW
Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559
[TBL] [Abstract][Full Text] [Related]
9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
11. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
[TBL] [Abstract][Full Text] [Related]
13. Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Zhang Y; Xiao Y; Dong Q; Ouyang W; Qin Q
J Food Sci; 2019 Apr; 84(4):904-910. PubMed ID: 30866043
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
15. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
16. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
17. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
18. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
19. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
[TBL] [Abstract][Full Text] [Related]
20. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
Alikian M; Gale RP; Apperley JF; Foroni L
Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]